Wugen, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2018-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.wugen.com
Clinical Trials
7
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
- Conditions
- T-cell Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma
- Interventions
- First Posted Date
- 2024-07-23
- Last Posted Date
- 2025-07-17
- Lead Sponsor
- Wugen, Inc.
- Target Recruit Count
- 125
- Registration Number
- NCT06514794
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Washington University Saint Louis, Saint Louis, Missouri, United States
A Phase 1b Study of WU-NK-101 in Combination With Cetuximab
- Conditions
- Colorectal Cancer MetastaticSquamous Cell Carcinoma of Head and Neck
- Interventions
- First Posted Date
- 2023-01-06
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Wugen, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05674526
- Locations
- 🇺🇸
UCSF, San Francisco, California, United States
🇺🇸Montefiore Medical Center, Bronx, New York, United States
A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007
- Conditions
- T-cell Lymphoblastic LymphomaT-cell Acute Lymphoblastic Leukemia
- First Posted Date
- 2022-08-22
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Wugen, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT05509855
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Childrens Hospital LA, Los Angeles, California, United States
🇺🇸Washington University, Saint Louis, Missouri, United States
A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)
- First Posted Date
- 2022-07-22
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Wugen, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT05470140
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Stanford Healthcare, Palo Alto, California, United States
🇺🇸Norton Health Care, Louisville, Kentucky, United States
A Phase 1/2 Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL
- Conditions
- Lymphoblastic LymphomaT-cell Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2021-07-30
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Wugen, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT04984356
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Moffit Cancer Center, Tampa, Florida, United States